Sign inJoin waitlistJoin the waitlist

Shebli Atrash

Associate Professor, Cancer Medicine · Wake Forest University Baptist Medical Center

Credentials: · · · · · ·

History

Wake Forest University Baptist Medical Center
Present

Hematology and Medical Oncology
University of Arkansas for Medical Sciences
2019–2022
Internal Medicine
St Barnabas Hospital
2016–2019
Univ of Arkansas Coll of Med
2012–2016
University of Damascus
2001–2004

Research

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Journal of Clinical Oncology · 2023 · 271 citations
Extramedullary multiple myeloma
Review · Leukemia · 2020 · 191 citations
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Blood · 2025 · 135 citations

Peter Voorhees
40 papers
Barry Paul
30 papers · 6 as a fellow
Joseph McGuirk
29 papers
LS
Leyla Shune
26 papers
Manisha Bhutani
26 papers · 1 as a fellow
Saad Usmani
26 papers
Christopher Ferreri
22 papers · 7 as a fellow
NA
Nausheen Ahmed
22 papers
DH
Doris Hansen
21 papers
Jack Khouri
21 papers
Aimaz Afrough
20 papers
Danai Dima
20 papers · 7 as a fellow

Clinical trials

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Principal investigator · Active not recruiting · Phase 2
Academic and Community Cancer Research United
2022–2027
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
Principal investigator · Withdrawn · Phase 2
Wake Forest University Health Sciences
2021–2027
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Principal investigator · Active not recruiting · Phase 1, Phase 2
Wake Forest University Health Sciences
2021–2032
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Principal investigator · Completed · Phase 1, Phase 2
Wake Forest University Health Sciences
2019–2024